fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ondansetron HCL dihydrate

All injection strengths: not a benefit

Zofran · DIN 02213745 · 2 mg/mL · injection solution-2mL Pk

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2017-03-14 — choose a marketed DIN from the same-category list.Discontinued March 14, 2017 · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2017-03-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-03-14 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Zofran · DIN 02213745 Manufacturer: Novartis Pharma Canada Inc.; listing date 2009-05-20 Health Canada: Cancelled post market since 2017-03-14 · brand ZOFRAN · ATC A04AA01 ONDANSETRON · form Solution · route Intravenous · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 2 MG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zofran: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02213745)

Source record
DIN 02213745: Zofran Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 562200014; group id 670; item number 1660; lccId None; manufacturer id NOV Source form: Inj Sol-2mL Pk; strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213745 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43137
Interchangeable products
Auro-Ondansetron Injection · DIN 02491524 · not recorded Ondansetron Hydrochloride Dihydrate Inj · DIN 02274418 · not recorded Ondansetron Injection USP · DIN 02464578 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since March 14, 2017 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (A04A, A04AA): coverage varies; not interchangeable

  • Granisetron (Kytril): limited Use 326, 454, not a benefit
  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, not a benefit
  • Nabilone (Cesamet): general benefit, not a benefit
  • Aprepitant (Emend Tri-Pack): limited Use 452, 453
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Adults (18-64 years of age) Ondansetron Injection USP (ondansetron hydrochloride dihydrate) is indicated for: • the prevention of nausea and vomiting associated with emetogenic chemotherapy, including high dose cisplatin. • the prevention and treatment of postoperative nausea and vomiting. 1.1 Pediatrics Prevention of Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy (e.g. cisplatin) • Pediatrics (< 18 years): Health Canada has not authorized an indication for pediatric use. Prevention of Nausea and Vomiting Associated With Less Emetogenic Chemotherapy • Pediatrics (4-12 years of age): Intravenous ondansetron was effective and well tolerated when given to children 4-12 years of age (see 4.2 Recommended Dose and Dosage Adjustment). • Pediatrics (<4 years of age): Ondansetron Injection USP is not indicated for the treatment of children less than 4 years old. Prevention and Treatment of Post-Operative Nausea and Vomiting • Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Prevention of Nausea and Vomiting Associated with Emetogenic C… https://pdf.hres.ca/dpd_pm/00070913.PDF PM date: May 17, 2023 Source product: ONDANSETRON INJECTION USP; DIN 02464578; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Zofran: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026